Money & Banking

MedGenome raises additional $10 mn in Series C from HDFC

Priyanka Pani Mumbai | Updated on March 05, 2018 Published on March 05, 2018

Leading genetics diagnostics firm MedGenome Labs Ltd said it has completed its Series C round of $40 million after getting an additional $10 million from private lender HDFC Ltd, insurer HDFC Life and HDFC Asset Management.

Last August, it had raised $30 million in Series C from Sequoia India and Sofina s.a., with participation by Zodius Capital; Kris Gopalakrishnan, co-founder and former CEO of Infosys; and Lakshmi Narayanan, former CEO of Cognizant.

MedGenome said in a statement it would use the funds to expand the clinical genomic testing market by penetrating all the Tier-II and Tier-III cities and democratise critical genetic tests such as non-invasive pre-natal screening (NIPT) and newborn genetic testing. It also plans to establish more genetic centres in hospitals across the country to support clinicians and to enable patients to take informed decisions.

"We believe understanding genetic information can have a big impact on the Indian healthcare industry through early detection of disease risk and development of new medicines. We are happy to see an Indian company take a lead in a deep technology area such as genomics and have decided to support MedGenome in its endeavour to make genetic tests affordable and accessible widely," said Deepak Parekh, Chairman, HDFC Group.

MedGenome has completed over 100,000 genomic tests and supported clinicians in diagnosing more than 40 per cent of unresolved cases. About 6 per cent of the children born in India have inherited paediatric diseases, which is double the worldwide occurrence rate. Sam Santhosh, founder and Chairman of MedGenome, said the goal is to significantly reduce the burden of inherited diseases in India and assist clinicians in implementing precision medicine.

MedGenome claims to operate the largest CAP-accredited Next Generation Sequencing (NGS) lab in South Asia and its diagnostics tests include many breakthroughs for genetic diagnostics including the first proprietary liquid biopsy (OncoTrack) for monitoring cancer treatment, non-invasive prenatal screening test (NIPT) for pregnant women, carrier screening for couples planning for children, and whole exome sequencing for cost-effective identification of rare mutations.

Published on March 05, 2018

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.